Plasmapheresis
CRRT
LCAP
Literature about conditions for therapeutic apheresis is indicated.
- Tamaki et al.
- Cryofiltration apheresis for major ABO-incompatible kidney transplantation.
- Ther Apher. 1998 2:308-10, 1998.
- Tanabe K.
- Japanese experience of ABO-incompatible living kidney transplantation.
- Transplantation. 84:S4-7, 2007.
- Beige et al.
- Immunoadsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis.
- Am J Transplant. 3:1459, 2003.
About Nephrology
Please see below for therapeutic apheresis application for Nephrology.
- Kosaka et al.
- Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease.
- Intern Med. 38:102-11, 1999.
- Hidaka et al.
- Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
- J Clin Apheresis. 16:74-81, 2001.
- Yamaji et al.
- Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.
- Ther Apher. 6:402-12, 2002.
- Sawada et al.
- Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
- Current Pharmaceutical Design 9:307-21, 2003.
- Fukunaga et al.
- Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy.
- J Gastroenterol. 38:684-9, 2003.
- Kohgo et al.
- Leukocytapheresis for treatment of IBD.
- J Gastroenterol. 38 Suppl 15:51-4, 2003.
- Sawada K.
- Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
- Dis Colon Rectum. 46 Suppl: S66-77, 2003.
- Andoh et al.
- Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
- J Gastroenterol. 39:1150-7, 2004.
- Klingel et al.
- Leukocytapheresis (LACP) for chronic active ulcerative colitiss - final results of a pilot trial and design of the german randomized, double-blind, placebo-controlled multicenter trial (MICELL-UC trial).
- J Clinic Apheresis 20, Abs 4, 2005.
- Sawada et al.
- Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
- Am J Gastroenterol. 100:1362-9, 2005.
- Sawada et al.
- Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.
- Dig Dis Sci. 50:767-73, 2005.
- Ashizuka et al.
- Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
- Ther Apher Dial. 10:54-8, 2006.
- Sandborn WJ.
- Preliminary data on the use of apheresis in inflammatory bowel disease.
- Inflamm Bowel Dis. 12 Suppl 1:S15-21, 2006.
- Matsumoto et al.
- Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
- Ther Apher Dial. 12:484-90, 2008.
- Dittrich et al.
- Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A.
- Inflamm Bowel Dis. 14:1466-7, 2008.
- Mitsuyama et al.
- Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis.
- Ther Apher Dial. 12:271-7, 2008.
- Mitsuyama et al.
- Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
- Curr Pharm Des. 15:2110-9, 2009.
- Mitsuyama et al.
- Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
- Cytotherapy. 11:229-37, 2009.
- Muratov et al.
- Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
- J Clin Apher. 25:287-93, 2010.
- Ashida et al.
- A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
- Transfus Apher Sci. 44:113-7, 2011.
- Senf et al.
- Bilirubin-adsorption in 23 critically ill patients with liver failure.
- Int J Artif Organs. 27:717-22, 2004.
- Adani et al.
- Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction.
- Transplant Proc. 39:1904-6, 2007.
- Taniguchi et al.
- Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.
- Transplantation. 81:1747-9, 2006.
- Fujiwara et al.
- Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load.
- Hepatol Res. 37:701-10, 2007.
- Kaneko et al.
- Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.
- Hepatol Res. 40:1072-1081, 2010.
- Ohara et al.
- Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
- Hepatogastroenterology. 58:133-6, 2011.
About Gastroenterology
Please see below for therapeutic apheresis application for Gastroenterology.
- Liang et al.
- Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.
- Arthritis and Rheumatism, vol. 32, No. 9, 1989.
- Gaubitz et al.
- Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.
- J Autoimmun. 11:495-501, 1998.
- Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus.
- Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus.
- Arthritis and Rheumatism, vol. 50, No. 11, 2004.
- Sugimoto et al.
- Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis.
- Ther Apher Dial. 10:187-92, 2006.
- Yamaji et al.
- Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis.
- Ther Apher Dial. 12:298-305, 2008.
- Loo et al.
- Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis.
- Transfus Apher Sci. 43:335-40, 2010.
- Liu et al.
- Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: a retrospective study.
- J Clin Apher. 26:174-80, 2011.
- Inoh et al.
- Randomized Open Trial to Compare the Effectiveness of Cryofiltration and Leukapheresis in Methotrexate-Resistant RA patients.
- Jpn J Apheresis 16:189-190, 1997.
- Sueoka A.
- Therapeutic apheresis application using membrane plasma fractionation technology: present scope and limitations.
- Ther Apher. 4:211-2, 2000.
- Matsuda et al.
- Double filtration plasmapheresis for the treatment of a rheumatoid arthritis patient with extremely high level of c-reactive protein.
- Ther Apher Dial. 8:404-8, 2004.
- Yu et al.
- A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
- J Clin Rheumatol. 13:193-8, 2007.
About Rheumatology
Please see below for therapeutic apheresis application for Rheumatology.
- Geiss et al.
- Low density lipoprotein apheresis by membrane differential filtration (Cascade filtration).
- Therapeutic Apheresis. 3:199-202, 2000.
- Julius et al.
- Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
- Int J Artif Organs. 25:1180-8, 2002.
- Klingel et al.
- From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis.
- Ther Apher Dial. 7:350-8, 2003.
- Klingel et al.
- Lipidfiltration - safe and effective methodology to perform lipid-apheresis.
- Transfusion and Apheresis Science. 30:245-254, 2004.
- Julius et al.
- Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.
- J Clin Apher. 22:215-23, 2007.
- Fernández-Fuertes et al.
- Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia.
- Ther Apher Dial. 14:484-5, 2010.
About Cardiovascular
Please see below for therapeutic apheresis application for Cardiovascular.
- Splendiani et al.
- Plasmaperfusion on triptophan columns can improve the clinical outcome of patients affected with myasthenia gravis.
- Artif Cells Blood Substit Immobil Biotechnol. 31:69-79, 2003.
- Chiu et al.
- Pulmonary function study of myasthenia-gravis patients treated with double filtration plasmapheresis.
- J Clin Apher. 18:125-8, 2003.
- Wagner et al.
- [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
- Dtsch Med Wochenschr. 133:2377-82, 2008. German.
- Nagane et al.
- Early aggressive treatment strategy against myasthenia gravis.
- Eur Neurol. 65:16-22, 2011.
- Haupt et al.
- Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
- Ther Apher. 4:198-200, 2000.
- Okamiya et al.
- Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome.
- Ther Apher Dial. 8:248-53, 2004.
- Seta et al.
- Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
- Clin Neurol Neurosurg. 107:491-6, 2005.
- Arakawa et al.
- Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study.
- Brain Dev. 27:431-3, 2005.
- Ota et al.
- Neutrophil activation in immunoadsorption.
- Ther Apher. 4:229-34, 2000.
- Galldiks et al.
- Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
- Eur Neurol. 66:183-9, 2011.
- Noseworthy et al.
- A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.
- Neurology. 56:1514-22, 2001.
- Ramunni et al.
- A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
- Ther Apher Dial. 12:250-4, 2008.
- Mauch et al.
- [Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses : Clinical data of 14 patients].
- Nervenarzt. 82:1590-5, 2011. German
- Trebst et al.
- Immunoadsorption Therapy for Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. Blood Purif. 33:1-6, 2011.
About Neurology
Please see below for therapeutic apheresis application for Neurology.
- El-Achkar et al.
- Approach to acute renal failure with multiple myeloma: role of plasmapheresis.
- Ther Apher Dial. 9:417-22, 2005.
About Hematology
Please see below for therapeutic apheresis application for Hematology.
- Luftl et al.
- Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
- Br J Dermatol. 149:598-605, 2003.
- Herrero-González et al.
- Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
- Clin Exp Dermatol. 30:519-22, 2005.
About Dermatology
Please see below for therapeutic apheresis application for Dermatology.
- Brunner et al.
- Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial.
- Retina 20:483-91, 2000.
- Klingel et al.
- Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology.
- Ther Apher. 6:271-81, 2002.
- Klingel et al.
- Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine.
- Transfus Apheresis Sci. 29:71-84, 2003.
- Pulido et al.
- Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).
- J Clin Apheresis. 20:185-194, 2005.
- Koss et al.
- Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.
- Graefes Arch Clin Exp Ophthalmol. 247:1297-306, 2009.
About Ophthalmology
Please see below for therapeutic apheresis application for Ophthalmology.
- Mösges et al.
- Quality of life in patients with idiopathic sudden hearing loss: comparison of different therapies using the Medical Outcome Short Form (36) Health Survey questionnaire.
- Otol Neurotol. 29:769-75, 2008.
- Mösges et al.
- Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial.
- Eur Arch Otorhinolaryngol. 266:943-53, 2009.
- Klingel et al.
- Rheopheresis for sudden sensorineural hearing loss.
- Atheroscler Suppl. 10:102-6, 2009.
About Otolaryngology
Please see below for therapeutic apheresis application for Otolaryngology.
Please feel free to send us any questions you may have about our products and support.
